As Essential Covid-19 Treatments and Services Become More Needed, Healthcare Cloud Computing Is Booming - Seite 2

ITOCO INC. (OTCPK: ITMC) BREAKING NEWS: ITOCO completes Immutable Virus Test Result secure web application - ITOCO has successfully developed and deployed a secure software-as-a-service (SaaS) web-based application for administering the Immutable Virus Test Result Verification System and has made it available at ImmutableTest.com.   This new development, combined with the previously announced deployment of the blockchain smart contract, demonstrates the rapid progress the company is making at commercializing this important patent-pending technology. 

Key features of the web-based application include that it: 

>> Is available at www.ImmutableTest.com and within the www.ArgoBlock.com Platform Wallet.

>> Enables System Administrators to add anonymized Users to the blockchain to be updated by Virus Testing Systems that are whitelisted

>> Enables System Administrators to whitelist Virus Testing Systems to enable them to update virus test result data for users on the blockchain

>> Provides a user interface for customers for displaying user and test result data from the blockchain as easy-to-read tables

"The ImmutableTest.com application represents an accelerated step forward in bringing this patent-pending technology to market quickly," said Greg Marlin, CEO/CTO of DATANet Corp and developer of the application. "The next step in commercializing this technology is the development of the user-facing mobile application, which combines both blockchain and biometric technologies. Development has already started on this for both Android and iOS and we expect to be able to make an announcement on that shortly."

"This latest technology release demonstrates our continued commitment to commercializing our technology portfolio. This web-based application technology will form an important foundation for future releases to come." said Michael Paul, CEO of ITOCO.   Read more about ITMC at:  https://www.itoco.net/

Other recent developments in the markets include:

GeoVax Labs, Inc. (NASDAQ: GOVX) recently announced the signing of a Patent and Biological Materials License Agreement (the "License Agreement") with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID's patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.